475 related articles for article (PubMed ID: 35244503)
1. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
2. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
3. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
4. Remodeling tumor microenvironment with nanomedicines.
Martin JD; Miyazaki T; Cabral H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
[TBL] [Abstract][Full Text] [Related]
5. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
Sa P; Sahoo SK; Dilnawaz F
Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
8. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
9. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.
Zhang J; Sun J; Li C; Qiao H; Hussain Z
J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
Zhang Y; Li J; Pu K
Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
[TBL] [Abstract][Full Text] [Related]
11. Responsive and activable nanomedicines for remodeling the tumor microenvironment.
Zhang Y; Han X; Nie G
Nat Protoc; 2021 Jan; 16(1):405-430. PubMed ID: 33311713
[TBL] [Abstract][Full Text] [Related]
12. Strategies targeting tumor immune and stromal microenvironment and their clinical relevance.
Hu M; Huang L
Adv Drug Deliv Rev; 2022 Apr; 183():114137. PubMed ID: 35143893
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
15. Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.
Avgoustakis K; Angelopoulou A
Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399240
[TBL] [Abstract][Full Text] [Related]
16. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
David A
Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
[TBL] [Abstract][Full Text] [Related]
17. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
Zhou L; Wang H; Li Y
Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
[TBL] [Abstract][Full Text] [Related]
18. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
19. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
[TBL] [Abstract][Full Text] [Related]
20. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
